PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32425601-13	2020	Mechanistic studies revealed that EVO suppresses metastatic through suppressing epithelial-mesenchymal transition (EMT) as indicated by elevating the expression of epithelial marker E-cadherin and reducing the expression of mesenchymal markers N-cadherin and vimentin, as well as EMT transcription factors Snail and MMPs.	evodiamine	34-37	vimentin	Homo sapiens	259-267	
35163776-10	2022	Migration and invasion analysis showed that evodiamine has anti-metastatic ability on Hep3B and Huh-7 cells and reduces the level of vimentin, an EMT marker.	evodiamine	44-54	vimentin	Homo sapiens	133-141	
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	vimentin	Homo sapiens	202-210